Müller, Sabrina
Junker, Sophia
Wilke, Thomas
Lommatzsch, Albrecht
Schuster, Alexander K.
Kaymak, Hakan
Ehlken, Christoph
Ziemssen, Focke
Funding for this research was provided by:
Bayer Vital GmbH
Article History
Received: 2 February 2021
Accepted: 9 May 2021
First Online: 2 June 2021
Declarations
:
: The study was approved by the independent Ethics Commissions of the Universität Rostock, Germany.
: Not applicable.
: Sabrina Mueller and Sophia Junker are employees of Ingress-Health. Ingress-Health work was financially supported by Bayer Vital GmbH. Thomas Wilke is an employee of IPAM and has received honoraria from several pharmaceutical/consultancy companies (Novo Nordisk, Abbvie; Merck; GSK, BMS, LEO Pharma, Astra Zeneca, Bayer, Boehringer Ingelheim, Pharmerit). Focke Ziemssen received grants and personal fees from Allergan, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Clearside, MSD Sharp & Dohme, Novartis, Novo Nordisk, Oxurion, Regeneron and Roche. Alexander K. Schuster holds the professorship for ophthalmic healthcare research endowed by „Stiftung Auge“ and financed by „Deutsche Ophthalmologische Gesellschaft“ and „Berufsverband der AugenärzteDeutschlands e.V.“ He received research funding from Allergan, Bayer Vital, Novartis, PlusOptix, and Heidelberg Engineering. Dr. Ehlken reports personal fees from Bayer Vital GmbH, during the conduct of the study; personal fees from Allergan, outside the submitted work. Dr Kaymak has nothing to disclose. Dr. Lommatzsch reports personal fees from Bayer, during the conduct of the study.